NCT06693154 is a clinical trial in Necrotising Enterocolitis Neonatal, sponsored by Ankara Yildirim Beyazıt University.

Who is sponsoring NCT06693154?

NCT06693154 is sponsored by Ankara Yildirim Beyazıt University.

What condition does NCT06693154 study?

NCT06693154 studies Necrotising Enterocolitis Neonatal.

Is NCT06693154 still recruiting?

NCT06693154 is currently completed. Last updated 18 November 2024.

Last reviewed 2024-11-18 · How we verify

NCT06693154

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Calprotectin Levels in Necrotizing Enterocolitis

Completed Last updated 18 November 2024

What this trial tests

trial in Necrotising Enterocolitis Neonatal in 59 participants. Completed in 1 June 2024.

Timeline

1 June 2022

Primary endpoint
1 January 2024

1 June 2024

Quick facts

Lead sponsor	Ankara Yildirim Beyazıt University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	59
Start date	1 June 2022
Primary completion	1 January 2024
Estimated completion	1 June 2024
Sites	1 location across Turkey (Türkiye)

Conditions studied

Necrotising Enterocolitis Neonatal — all drugs for Necrotising Enterocolitis Neonatal →

Sponsor

Ankara Yildirim Beyazıt University

Who can join

Adults 3 Days to 30 Days, any sex, with Necrotising Enterocolitis Neonatal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Necrotizing enterocolitis (NEC) is a serious condition that can affect premature babies, leading to complications like intestinal damage and infection. In our study, we measured specific markers (called calprotectin) in blood and stool to understand how severe NEC is and predict outcomes. We found that these markers were higher in babies with more severe NEC (stage 3), especially in those who needed surgery or sadly did not survive. This information can help doctors detect NEC earlier, understand its severity, and make better decisions for treating affected babies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A comparative study of serum and fecal calprotectin levels in necrotizing enterocolitis.
Erol S, Tayman C, Korkut S, Çakir U, et al · · 2025 · PMID 40784368 · DOI 10.1016/j.jped.2025.101428

Verify or expand the search:

Other Ankara Yildirim Beyazıt University trials

Trials by the same sponsor.

NCT07530835 — Occlusal Changes After Modified Hall Technique in Molars Affected by Molar-Incisor Hypomineralization · NA · not yet recruiting
NCT07496853 — Effect of Upper Extremity Support on Spatiotemporal Parameters of Gait in Individuals With Stroke · NA · recruiting
NCT07441668 — Comfort Intervention in PICU Children · NA · not yet recruiting
NCT07431151 — Effects of Intensive Virtual Reality-Based Balance and Gait Training on Activity Performance and Quality of Life in Suba · NA · recruiting
NCT07247903 — The Impact of Patient Education Delivered Through Virtual Reality · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06693154 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ankara Yildirim Beyazıt University
Last refreshed: 18 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06693154.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing